Effect of alemtuzumab or basiliximab induction therapy on graft function and survival of kidneys from donors after cardiac death.

Documenti analoghi

• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
  di: Haynes, R, et al.
  Pubblicazione: (2014)
• Results of a Large Randomized Controlled Trial of Alemtuzumab-Versus Basiliximab-Based Induction Therapy in Kidney Transplantation
  di: Haynes, R, et al.
  Pubblicazione: (2014)
• Impact of monoclonal antibody based-induction therapy on postoperative graft function and survival of kidneys from non-heart-beating donors.
  di: Plata-Munoz, J, et al.
  Pubblicazione: (2007)
• The deceased donor score system in kidney transplants from deceased donors after cardiac death.
  di: Plata-Munoz, J, et al.
  Pubblicazione: (2010)
• Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial.
  di: Haynes, R, et al.
  Pubblicazione: (2014)